Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PROPAFENONE FOR SINUS RHYTHM RECOVERY AND SUPPORT IN PATIENTS WITH PERSISTENT FORM OF AURICULAR FIBLILLATION. “PROMETHEUS” – OPENED MULTICENTER STUDY IN RUSSIAN FEDERATION

Full Text:

Abstract

Aim. To study efficiency and safety of propafenone internally used for recovery and support of sinus rhythm in patients with the persistent form of auricular fibrillation (AF). Material and methods. 503 patients with the persistent form of AF, aged 31-68 years were included into multicenter study. Patients were randomized into 2 groups. First group included 285 patients, who were prescribed propafenone (Propanorm, PRO.MED.CS Praha a.s., Czech Republic) in a single per oral dose of 600 mg for AF paroxysm relief. Second group included 218 patients, who took propafenone for AF paroxysm prevention in daily dose of 450 mg. Efficiency of sustaining antiarrhythmic therapy was assessed in 1, 3 and 9 months after the treatment started by carrying out daily monitoring of EKG. Results. Propafenone in a single per oral dose of 600 mg leaded to sinus rhythm recovery in 230 (81%) patients. Average time for sinus rhythm recovery made up 210±50 minutes. Relief, caused by propafenone within 4 hours after taking the drug, was observed in 182 (64%) patients. Propafenone in dose of 450 mg daily lets keep sinus rhythm after 1 month of treatment in 161 patients (74%), after 3 months – in 130 patients (60%) and after 9 months – in 98 patients (45%). Effect of preventive antiarythmic therapy within first 3 months of treatment with propafenone can be regarded good, and within 9 months – satisfactory. Conclusion. Propafenone in per oral single dose of 600 mg is an efficient method of sinus rhythm recovery in patients with the persistent form of AF, and its long-term usage in dose 450 mg daily is an efficient and safe method of sinus rhythm support.

About the Authors

I. G. Fomina
Moscow medical academy named after Setchenov I.M.
Russian Federation


A. I. Tarzimanova
Moscow medical academy named after Setchenov I.M.
Russian Federation


A. V. Vetluzsky
Moscow medical academy named after Setchenov I.M.
Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation




Russian Federation


В. Шульман
Красноярская медицинская академия


М. Маринина
Красноярская медицинская академия


Г. Матюшин
Красноярская медицинская академия


Л. Пичковская
Красноярская медицинская академия


Н. Боровков



О. Вилкова



References

1. Боровков Н.Н., Мазалков К.В., Советская Е.В., Востокова А.А., Малышева Е.Б., Королева Т.В., Вилкова О.Е. Эффективность пропафенона в купировании пароксизмов фибрилляции предсердий. // Российский кардиологический журнал, 2003, №5 (43), стр. 65-67.

2. Захар А., Антонченко И.В., Борисова Е.В., Попов С.В., Курлов И.О. Клиническая эффективность и безопасность купирования пароксизмов фибрилляции предсердий пропафеноном. // Россий- ский кардиологический журнал, 2003, №4, стр. 59-62.

3. Миллер О.Н., Бондарева З.Г., Пирогова Л.А. Пропафенон в профилактике пароксизмов фибрилляции предсердий у больных с некоронарогенными заболеваниями миокарда. // Российский кардиологический журнал, 2002, №3 (35), стр. 41-45.

4. Татарский Б.А. Протекторный эффект пропафенона при пароксизмальных реципрокных атриовентрикулярных тахикардиях. // Российский кардиологический журнал, 2004, №1 (45), стр. 45-53.

5. Скибицкий В.В., Кудряшов Е.А., Спиропулос Н.А. Изучение эффективности пропафенона при пароксизмальной фибрилляции предсердий. // Российский кардиологический журнал, 2004, №6, стр. 68-70.

6. Dogan A, Ergene O, Nazli C. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study.// Acta Cardiol., 2004 Jun; 59(3), р.255-261.

7. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2001; 22:1852-1923

8. Kochiadakis GE, Igoumenidis NE, Hamilos MI et al. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses.// Chest., 2004, Feb, vol 125(2), р.377-383.

9. Boriani G, Biffi M., Capucci A Oral propafenone to convert recent onset atrial fibrillation in patients with and without underlying heart disease: a randomized controlled trial // Ann. Intern. Med. 1997; 126: 621-625.

10. Capucci A, Villiani G., Aschieri D. Safety of oral propafenone in the convertion of recept-onset atrial fibrillation to sinus rhythm: a prospective parallel placebo – controlled multicentred study. // Int. J. Cardiol., 1999; 68: 187-196.


For citation:


Fomina I.G., Tarzimanova A.I., Vetluzsky A.V., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., . PROPAFENONE FOR SINUS RHYTHM RECOVERY AND SUPPORT IN PATIENTS WITH PERSISTENT FORM OF AURICULAR FIBLILLATION. “PROMETHEUS” – OPENED MULTICENTER STUDY IN RUSSIAN FEDERATION. Rational Pharmacotherapy in Cardiology. 2006;2(1):37-40. (In Russ.)

Views: 215


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)